NCT02883049 — drugset

Summary

This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Chemotherapy drugs, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.

Timeline

Start: 2012-02-29
Primary completion: 2022-12-31
Completion: 2026-03-31

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clofarabine	Other / unclassified	—	Intravenous
Subject	Cyclophosphamide	Other / unclassified	—	Intravenous
Subject	Cytarabine	Small molecule	—	Intrathecal
Subject	Etoposide	Small molecule	—	Intravenous
Subject	Hydrocortisone	Other / unclassified	—	Intrathecal
Subject	Methotrexate	Small molecule	—	Intrathecal
Subject	dasatinib anhydrous	Small molecule	—	Oral
Background	Daunorubicin	Small molecule	—	Intravenous
Background	Dexamethasone	Small molecule	—	Oral
Background	Doxorubicin	Other / unclassified	—	Intravenous
Background	Leucovorin	Small molecule	—	Oral
Background	MERCAPTOPURINE ANHYDROUS	Small molecule	—	Oral
Background	Pegaspargase	Protein / enzyme biologic	—	Intravenous
Background	Prednisone	Other / unclassified	—	Oral
Background	Thioguanine	Small molecule	—	Oral
Background	Vincristine	Small molecule	—	Intravenous

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Summary

Timeline

Publications

Drugs

Indications